Park SC, Kim DW, Park EC, et al. Mortality of patients with chronic obstructive pulmonary disease: a nationwide population based cohort study. Korean J Intern Med. 2019;34(6):1272–8.

Article  PubMed  PubMed Central  Google Scholar 

Global Initiative for Asthma 2022. Global strategy for asthma management and prevention. Available at: https://ginasthma.org/wp-content/uploads/2022/05/GINA-Main-Report-2022-FINAL-22-05-03-WMS.pdf. Accessed 9 Nov 2023.

Miravitlles M, Roman-Rodríguez M, Ribera X, et al. Inhaled corticosteroid use among COPD patients in primary care in Spain. Int J Chronic Obstr Pulm Dis. 2022;17:245–58.

Article  CAS  Google Scholar 

Quint JK, Ariel A, Barnes PJ. Rational use of inhaled corticosteroids for the treatment of COPD. NPJ Prim Care Respir Med. 2023;33(1):27.

Article  PubMed  PubMed Central  Google Scholar 

GOLD 2023 guidelines. Available at: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf. Accessed 12 March 2024.

Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease: a systematic review. Am J Respir Crit Care Med. 2021;203:689-98. https://doi.org/10.1164/rccm.202005-1854OC.

Calverley P. Reigniting the TORCH: chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited. Am J Respir Crit Care Med. 2021;203(5):531–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax. 2013;68(6):499–500.

Article  PubMed  Google Scholar 

Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8:59–65.

Article  PubMed  PubMed Central  Google Scholar 

Mkorombindo T, Dransfield MT. Inhaled corticosteroids in chronic obstructive pulmonary disease: benefits and risks. Clin Chest Med. 2020;41(3):475–84.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Li S, Zhou W, et al. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020;17(4):462–9.

Article  PubMed  Google Scholar 

Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;77: 105950.

Article  CAS  PubMed  Google Scholar 

Suissa S. Inhaled corticosteroids and pneumonia mortality in COPD patients. Eur Respir J. 2019;54(3):1901276.

Article  PubMed  Google Scholar 

Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12: 691621.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lodise TP, Li J, Gandhi HN, et al. Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies. Int J Chronic Obstr Pulm Dis. 2020;15:2889–900.

Article  CAS  Google Scholar 

Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Proposal for pneumonia risk with ICS. Available at: https://osf.io/tegpk. Accessed 1 Jan 2024.

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Gjerdevik M, Heuch I. Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14:109.

Article  PubMed  PubMed Central  Google Scholar 

Asthma: diagnosis, monitoring and chronic asthma management. Available at: https://www.nice.org.uk/guidance/ng80/resources/asthma-diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621. Accessed 2 Nov 2023.

EpiGear International. Available at: https://www.epigear.com/index.html. Accessed 6 Nov 2023.

GRADE handbook. Introduction to GRADE handbook. Available at: https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 6 Nov 2023.

VOSviewer version 1.6.20. Available at: https://www.vosviewer.com/. Accessed 4 Nov 2023.

Litmaps (2023). Available at: https://www.litmaps.com/. Accessed 4 Nov 2023.

Wallace BC, Lajeunesse MJ, Schmid CH, et al. OpenMEE: Intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol. 2017;8(8):941–7.

Article  Google Scholar 

Thorlund K, Engstrom J, Wetterslev J, et al. Trial sequential analysis. Copenhagen trial unit. Available at: https://ctu.dk/tsa/. Accessed 4 Nov 2023.

Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146:45-55.

Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD J Chronic Obstr Pulm Dis. 2009;6(5):320–9.

Bansal S, Anderson M, Anzueto A, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. Prim Care Respir Med. 2021;31(1):29.

Article  PubMed  PubMed Central  Google Scholar 

Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chronic Obstr Pulm Dis. 2016;4(11):193–205.

Article  Google Scholar 

Beeh KM, Kuna P, Corradi M, et al. Comparison of Dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial. COPD. 2021;16:79–89.

Article  CAS  Google Scholar 

Betsuyaku T, Kato M, Fujimoto K, et al. A randomized trial of symptom-based management in Japanese patients with COPD. COPD. 2018;13:2409–23.

Article  CAS  Google Scholar 

Bhatt S, Dransfield M, Cockcroft J, et al. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. COPD. 2017;12:351–65.

Article  CAS  Google Scholar 

Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–9.

Article  CAS  PubMed  Google Scholar 

Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9(1):73.

Article  PubMed  PubMed Central  Google Scholar 

Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.

Article  CAS  PubMed  Google Scholar 

Calverley PMA, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med. 2010;104(12):1858–68.

Article  CAS  PubMed  Google Scholar 

Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–39.

Article  CAS  PubMed  Google Scholar 

Cheng SL, Su KC, Wang HC, et al. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des. 2014:601-7.

Covelli H, Pek B, Schenkenberger I, et al. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. COPD. 2015;1.

Doherty D, Tashkin D, Kerwin, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. COPD. 2012;57.

Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–81.

Article  PubMed  Google Scholar 

Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.

Article  CAS  PubMed  Google Scholar 

Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011;105(9):1322–30.

Article  PubMed  Google Scholar 

Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals ATS. 2021;18(5):788–98.

Article  Google Scholar 

Fatima S, Tariq F, Saqib Ur Rehman M, et al. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease. PJMHS. 2023;17(4):12–6.

Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med. 2008;102(8):1099–108.

Article  PubMed  Google Scholar 

Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334.